Theranostics 2017; 7(18):4566-4576. doi:10.7150/thno.19840 This issue
1. School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, China
2. Department of Radiation Oncology, the First Affiliated Hospital, Anhui Medical University, Hefei, 230022, China
3. School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China
* These authors contributed equally to this work.
Inhibition of the interaction between p53 and MDM2/MDMX has attracted significant attention in anticancer therapy development. We designed a series of in-tether chiral center-induced helical stabilized peptides, among which MeR/PhR effectively reactivated p53. The activation of p53 inhibits cell proliferation and induces apoptosis in both the MCF-7 normal tumor cell line and the PA-1 pluripotent cancer cell line with only minimal cellular toxicity towards normal cells or cancer cell lines with p53 mutations. The in vivo bioactivity study of the peptide in the ovarian teratocarcinoma (PA-1) xenograft model showed a tumor growth rate inhibition of 70% with a dosage of 10 mg/kg (one injection every other day). This is the first application of a stabilized peptide modulator targeting stem-like cancer cell both in vitro and in vivo and provides references to cancer stem cell therapy.
Keywords: Chirality-induced helical peptide, stem-like cancer cell, Cancer, p53-MDM2/MDMX.